{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:58:57Z","timestamp":1793505537508,"version":"4.5.0"},"reference-count":89,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,7]]},"DOI":"10.1097\/md.0b013e3181441a68","type":"journal-article","created":{"date-parts":[[2007,7,10]],"date-time":"2007-07-10T04:03:36Z","timestamp":1184040216000},"page":"242-251","source":"Crossref","is-referenced-by-count":603,"title":["Autoimmune Diseases Induced by TNF-Targeted Therapies"],"prefix":"10.1097","volume":"86","author":[{"given":"Manuel","family":"Ramos-Casals","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Brito-Zer\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Soria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Galiana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Bertolaccini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Jose","family":"Cuadrado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munther A.","family":"Khamashta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20210226","doi-asserted-by":"crossref","first-page":"625","DOI":"10.7326\/0003-4819-137-7-200210010-00030","article-title":"Infliximab-induced systemic lupus erythematosus.","volume":"137","author":"Ali","year":"2002","journal-title":"Ann Intern Med"},{"key":"R2-7-20210226","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.1445-5994.2005.00899.x","article-title":"Cutaneous vasculitis associated with infliximab in the treatment of rheumatoid arthritis.","volume":"35","author":"Anandacoomarasamy","year":"2005","journal-title":"Intern Med J"},{"key":"R3-7-20210226","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/01.rhu.0000152148.55133.ba","article-title":"Drug-induced lupus after treatment with infliximab in rheumatoid arthritis.","volume":"11","author":"Benucci","year":"2005","journal-title":"J Clin Rheumatol"},{"key":"R4-7-20210226","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.rdc.2004.01.003","article-title":"Consideration of the risk and treatment of tuberculosis in patients who have rheumatoid arthritis and receive biologic treatments.","volume":"30","author":"Bieber","year":"2004","journal-title":"Rheum Dis Clin North Am"},{"key":"R5-7-20210226","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1093\/rheumatology\/40.11.1317","article-title":"Etanercept-induced subacute cutaneous lupus erythematosus.","volume":"40","author":"Bleumink","year":"2001","journal-title":"Rheumatology (Oxford)"},{"key":"R6-7-20210226","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"R7-7-20210226","doi-asserted-by":"crossref","first-page":"634","DOI":"10.7326\/0003-4819-131-8-199910190-00031","article-title":"Autoimmune skin rashes associated with etanercept for rheumatoid arthritis.","volume":"131","author":"Brion","year":"1999","journal-title":"Ann Intern Med"},{"key":"R8-7-20210226","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1136\/ard.61.11.1031","article-title":"New onset systemic lupus erythematosus in a patient receiving etanercept for rheumatoid arthritis.","volume":"61","author":"Cairns","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"R9-7-20210226","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/art.11033","article-title":"Etanercept-induced lupus-like syndrome in a patient with rheumatoid arthritis.","volume":"48","author":"Carlson","year":"2003","journal-title":"Arthritis Rheum"},{"key":"R10-7-20210226","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/art.21702","article-title":"Infliximab-related lupus and associated valvulitis: a case report and review of the literature.","volume":"55","author":"Chadha","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R11-7-20210226","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1002\/1529-0131(200011)43:11<2383::AID-ANR2>3.0.CO;2-D","article-title":"Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials.","volume":"43","author":"Charles","year":"2000","journal-title":"Arthritis Rheum"},{"key":"R12-7-20210226","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1080\/03009740410005836","article-title":"Severe interstitial pneumonitis associated with infliximab therapy.","volume":"33","author":"Chatterjee","year":"2004","journal-title":"Scand J Rheumatol"},{"key":"R13-7-20210226","first-page":"2725","article-title":"Tumor necrosis factor-alpha antagonists induce lupus-like syndrome in patients with scleroderma overlap\/mixed connective tissue disease.","volume":"30","author":"Christopher-Stine","year":"2003","journal-title":"J Rheumatol"},{"key":"R14-7-20210226","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/j.gastro.2003.10.047","article-title":"The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients.","volume":"126","author":"Colombel","year":"2004","journal-title":"Gastroenterology"},{"key":"R15-7-20210226","first-page":"24","article-title":"Evolution of antinuclear antibodies and clinical patterns in patients with active rheumatoid arthritis with longterm infliximab therapy.","volume":"33","author":"Comby","year":"2006","journal-title":"J Rheumatol"},{"key":"R16-7-20210226","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/art.11187","article-title":"Comment on methotrexate pneumonitis after initiation of infliximab therapy for rheumatoid arthritis.","volume":"49","author":"Courtney","year":"2003","journal-title":"Arthritis Rheum"},{"key":"R17-7-20210226","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/art.10535","article-title":"Accelerated nodulosis and vasculitis following etanercept therapy for rheumatoid arthritis.","volume":"47","author":"Cunnane","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R18-7-20210226","doi-asserted-by":"crossref","first-page":"R545","DOI":"10.1186\/ar1715","article-title":"Mariette X; Club Rhumatismes et Inflammation. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey.","volume":"7","author":"De Bandt","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"R19-7-20210226","doi-asserted-by":"crossref","first-page":"234","DOI":"10.5414\/CNP62234","article-title":"Antineutrophil cytoplasmic antibody-associated necrotizing crescentic glomerulonephritis in a patient receiving treatment with etanercept for severe rheumatoid arthritis.","volume":"62","author":"Doulton","year":"2004","journal-title":"Clin Nephrol"},{"key":"R20-7-20210226","first-page":"S106","article-title":"Henoch Schonlein purpura following etanercept treatment of rheumatoid arthritis.","volume":"24","author":"Duffy","year":"2006","journal-title":"Clin Exp Rheumatol"},{"key":"R21-7-20210226","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/08916930400021378","article-title":"Autoantibodies profile of rheumatoid arthritis patients during treatment with infliximab.","volume":"38","author":"Elkayam","year":"2005","journal-title":"Autoimmunity"},{"key":"R22-7-20210226","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/ard.2004.024182","article-title":"Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha.","volume":"64","author":"Eriksson","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"R23-7-20210226","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1191\/0961203302lu236cr","article-title":"Drug-induced lupus following treatment with infliximab in rheumatoid arthritis.","volume":"11","author":"Favalli","year":"2002","journal-title":"Lupus"},{"key":"R24-7-20210226","doi-asserted-by":"crossref","first-page":"R666","DOI":"10.1186\/ar1724","article-title":"Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study.","volume":"7","author":"Flendrie","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"R25-7-20210226","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1053\/S0049-0172(03)00133-1","article-title":"Clusters of clinical and immunologic features in systemic lupus erythematosus: analysis of 600 patients from a single center.","volume":"33","author":"Font","year":"2004","journal-title":"Semin Arthritis Rheum"},{"key":"R26-7-20210226","first-page":"2041","article-title":"Leukocytoclastic vasculitis due to etanercept.","volume":"27","author":"Galaria","year":"2000","journal-title":"J Rheumatol"},{"key":"R27-7-20210226","first-page":"1232","article-title":"Long-term safety, efficacy and radiographic outcomes with etanercept treatment in patients with early rheumatoid arthritis.","volume":"32","author":"Genovese","year":"2005","journal-title":"J Rheumatol"},{"key":"R28-7-20210226","first-page":"56","article-title":"Clinical approach to cutaneous vasculitis.","volume":"17","author":"Gonzalez-Gay","year":"2005","journal-title":"Curr Opin Rheumatol"},{"key":"R29-7-20210226","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1002\/art.22238","article-title":"Development of sarcoidosis during etanercept therapy.","volume":"55","author":"Gonzalez-Lopez","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R30-7-20210226","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.semarthrit.2005.01.003","article-title":"Differentiating the efficacy of the tumor necrosis factor inhibitors.","volume":"34","author":"Haraoui","year":"2005","journal-title":"Semin Arthritis Rheum"},{"key":"R31-7-20210226","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/01.bor.0000198007.73320.6e","article-title":"Musculoskeletal manifestations and autoimmune diseases related to new biologic agents.","volume":"18","author":"Haraoui","year":"2006","journal-title":"Curr Opin Rheumatol"},{"key":"R32-7-20210226","first-page":"1917","article-title":"Infliximab-associated pneumonitis in rheumatoid arthritis.","volume":"33","author":"Hennum","year":"2006","journal-title":"J Rheumatol"},{"key":"R33-7-20210226","doi-asserted-by":"crossref","first-page":"E5","DOI":"10.1016\/S0190-9622(03)00869-7","article-title":"Cutaneous lupus erythematosus induced by infliximab.","volume":"52","author":"High","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"R33A-7-20210226","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum"},{"key":"R34-7-20210226","first-page":"2287","article-title":"Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series.","volume":"30","author":"Jarrett","year":"2003","journal-title":"J Rheumatol"},{"key":"R35-7-20210226","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/art.1780370206","article-title":"Nomenclature of systemic vasculitides. Proposal of an international consensus conference.","volume":"37","author":"Jennette","year":"1994","journal-title":"Arthritis Rheum"},{"key":"R36-7-20210226","first-page":"2061","article-title":"Treating leukocytoclastic vasculitis associated with etanercept therapy. Is it necessary to stop etanercept?","volume":"32","author":"Juan","year":"2005","journal-title":"J Rheumatol"},{"key":"R37-7-20210226","doi-asserted-by":"crossref","first-page":"946","DOI":"10.3346\/jkms.2006.21.5.946","article-title":"Etanercept-induced systemic lupus erythematosus in a patient with rheumatoid arthritis.","volume":"21","author":"Kang","year":"2006","journal-title":"J Korean Med Sci"},{"key":"R38-7-20210226","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/00054725-200305000-00005","article-title":"A lupus-like syndrome associated with infliximab therapy.","volume":"9","author":"Klapman","year":"2003","journal-title":"Inflamm Bowel Dis"},{"key":"R39-7-20210226","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/art.10803","article-title":"Methotrexate pneumonitis after initiation of infliximab therapy for rheumatoid arthritis.","volume":"47","author":"Kramer","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R40-7-20210226","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/rheumatology\/keg263","article-title":"Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy.","volume":"42","author":"Kroesen","year":"2003","journal-title":"Rheumatology"},{"key":"R41-7-20210226","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jaad.2004.10.788","article-title":"Safety and efficacy of over 7 years of etanercept therapy in a global population of patients with rheumatoid arthritis.","volume":"52","author":"Lebwohl","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"R42-7-20210226","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/01.rhu.0000239901.34561.5e","article-title":"Henoch-Schonlein purpura after etanercept therapy for psoriasis.","volume":"12","author":"Lee","year":"2006","journal-title":"J Clin Rheumatol"},{"key":"R43-7-20210226","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/art.20159","article-title":"Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate.","volume":"50","author":"Maini","year":"2004","journal-title":"Arthritis Rheum"},{"key":"R44-7-20210226","first-page":"355","article-title":"Pulmonary infiltrates after initiation of treatment with infliximab for adult Still's disease Arch Bronconeumol.","volume":"41","author":"Martin Carrasco","year":"2005","journal-title":""},{"key":"R45-7-20210226","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1080\/03009740600557249","article-title":"Demyelinating disease and cutaneous lymphocitic vasculitis after etanercept therapy in a patient with rheumatoid arthritis.","volume":"35","author":"Martinez-Taboada","year":"2006","journal-title":"Scand J Rheumatol"},{"key":"R46-7-20210226","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/rheumatology\/41.1.116","article-title":"Etanercept and infliximab associated with cutaneous vasculitis.","volume":"41","author":"McCain","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"R47-7-20210226","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/00004836-200305000-00010","article-title":"Hypersensitivity vasculitis with leukocytoclastic vasculitis secondary to infliximab.","volume":"36","author":"McIlwain","year":"2003","journal-title":"J Clin Gastroenterol"},{"key":"R48-7-20210226","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0889-857X(05)70239-8","article-title":"Drug-induced vasculitis.","volume":"27","author":"Merkel","year":"2001","journal-title":"Rheum Dis Clin North Am"},{"key":"R49-7-20210226","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1002\/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W","article-title":"Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides.","volume":"44","author":"Mohan","year":"2001","journal-title":"Arthritis Rheum"},{"key":"R50-7-20210226","first-page":"1955","article-title":"Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents.","volume":"31","author":"Mohan","year":"2004","journal-title":"J Rheumatol"},{"key":"R51-7-20210226","first-page":"740","article-title":"3rd, Barisoni L, Lydon E, Belmont HM. Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept.","volume":"32","author":"Mor","year":"2005","journal-title":"J Rheumatol"},{"key":"R52-7-20210226","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1093\/rheumatology\/keg388","article-title":"Polymyositis associated with infliximab treatment for rheumatoid arthritis.","volume":"42","author":"Musial","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"R53-7-20210226","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1097\/01.MIB.0000186408.07769.78","article-title":"Infliximab treatment does not induce organ-specific or nonorgan-specific autoantibodies other than antinuclear and anti-double-stranded DNA autoantibodies in Crohn's disease.","volume":"11","author":"Nancey","year":"2005","journal-title":"Inflamm Bowel Dis"},{"key":"R54-7-20210226","first-page":"268","article-title":"Infliximab-induced lupus or rheumatoid arthritis (RA) overlapping with systemic lupus erythematosus (SLE) unmasked by infliximab.","volume":"22","author":"Novak","year":"2004","journal-title":"Clin Exp Rheumatol"},{"key":"R55-7-20210226","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2165\/00003495-200565050-00006","article-title":"Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis.","volume":"65","author":"Nurmohamed","year":"2005","journal-title":"Drugs"},{"key":"R56-7-20210226","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1111\/j.1365-2133.2006.07195.x","article-title":"Adalimumab causing vasculitis.","volume":"154","author":"Orpin","year":"2006","journal-title":"Br J Dermatol"},{"key":"R57-7-20210226","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/art.22351","article-title":"Pulmonary sarcoidosis developing during infliximab therapy.","volume":"55","author":"O'Shea","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R58-7-20210226","first-page":"622","article-title":"Pulmonary complications of infliximab therapy in patients with rheumatoid arthritis.","volume":"33","author":"Ostor","year":"2006","journal-title":"J Rheumatol"},{"key":"R59-7-20210226","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/rheumatology\/kei227","article-title":"Infliximab-induced lupus-like reaction in a patient with psoriatic arthritis.","volume":"45","author":"Pallotta","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"R60-7-20210226","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/00054725-200405000-00016","article-title":"Diffuse alveolar hemorrhage after infliximab treatment of Crohn's disease.","volume":"10","author":"Panagi","year":"2004","journal-title":"Inflamm Bowel Dis"},{"key":"R61-7-20210226","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ejim.2006.02.010","article-title":"Infliximab-induced non-specific interstitial pneumonia and lupus-like eruption.","volume":"17","author":"Pataka","year":"2006","journal-title":"Eur J Intern Med"},{"key":"R62-7-20210226","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1093\/rheumatology\/kei220","article-title":"Drug-induced systemic lupus erythematosus in ankylosing spondylitis associated with infliximab.","volume":"45","author":"Perez-Garcia","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"R63-7-20210226","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/art.21336","article-title":"Granulomatous lung disease occurring during etanercept treatment.","volume":"53","author":"Phillips","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R64-7-20210226","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/01.smj.0000223696.21984.1f","article-title":"Enbrel-induced interstitial lung disease.","volume":"99","author":"Quintos-Macasa","year":"2006","journal-title":"South Med J"},{"key":"R65-7-20210226","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/01.md.0000216817.35937.70","article-title":"Vasculitis in systemic lupus erythematosus: prevalence and clinical characteristics in 670 patients.","volume":"85","author":"Ramos-Casals","year":"2006","journal-title":"Medicine (Baltimore)"},{"key":"R66-7-20210226","first-page":"2079","article-title":"Sensory neuropathy revealing necrotizing vasculitis during infliximab therapy for rheumatoid arthritis.","volume":"31","author":"Richette","year":"2004","journal-title":"J Rheumatol"},{"key":"R67-7-20210226","first-page":"760","article-title":"Infliximab induced chilblain lupus in a patient with rheumatoid arthritis.","volume":"32","author":"Richez","year":"2005","journal-title":"J Rheumatol"},{"key":"R68-7-20210226","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.jbspin.2004.05.008","article-title":"Cutaneous vasculitis and glomerulonephritis in a patient taking the anti-TNF alpha agent etanercept for rheumatoid arthritis.","volume":"71","author":"Roux","year":"2004","journal-title":"Joint Bone Spine"},{"key":"R69-7-20210226","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.tox.2004.12.025","article-title":"Drug-induced lupus.","volume":"209","author":"Rubin","year":"2005","journal-title":"Toxicology"},{"key":"R70-7-20210226","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0016-5085(99)70332-X","article-title":"Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.","volume":"117","author":"Rutgeerts","year":"1999","journal-title":"Gastroenterology"},{"key":"R71-7-20210226","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.jbspin.2006.02.010","article-title":"De Bandt M; CRI (Club Rhumatismes et Inflammation). Vasculitides induced by TNFalpha antagonists: a study in 39 patients in France.","volume":"73","author":"Saint Marcoux","year":"2006","journal-title":"Joint Bone Spine"},{"key":"R72-7-20210226","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1093\/rheumatology\/keg466","article-title":"Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis.","volume":"43","author":"Saravanan","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"R73-7-20210226","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/S1590-8658(03)00448-1","article-title":"Infliximab-induced lupus in Crohn's disease: a case report.","volume":"35","author":"Sarzi-Puttini","year":"2003","journal-title":"Dig Liver Dis"},{"key":"R74-7-20210226","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1136\/ard.2005.043166","article-title":"Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis.","volume":"65","author":"Schiff","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"R75-7-20210226","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1001\/archderm.142.1.115","article-title":"Infliximab-induced lupus erythematosus tumidus in a patient with rheumatoid arthritis.","volume":"142","author":"Schneider","year":"2006","journal-title":"Arch Dermatol"},{"key":"R76-7-20210226","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/art.21716","article-title":"Pulmonary fibrosis in a patient with rheumatoid arthritis treated with adalimumab.","volume":"55","author":"Schoe","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R77-7-20210226","first-page":"1467","article-title":"Giant cell arteritis in a patient taking etanercept and methotrexate.","volume":"31","author":"Seton","year":"2004","journal-title":"J Rheumatol"},{"key":"R78-7-20210226","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0140-6736(02)07714-0","article-title":"Drug-induced systemic lupus erythematosus associated with etanercept therapy.","volume":"359","author":"Shakoor","year":"2002","journal-title":"Lancet"},{"key":"R79-7-20210226","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1365-3083.2005.01570.x","article-title":"Immunology of cutaneous vasculitis associated with both etanercept and infliximab.","volume":"61","author":"Srivastava","year":"2005","journal-title":"Scand J Immunol"},{"key":"R80-7-20210226","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1093\/ndt\/gfh832","article-title":"Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis.","volume":"20","author":"Stokes","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"R81-7-20210226","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1365-2230.2004.01471.x","article-title":"Discoid lupus erythematosus-like eruption induced by infliximab.","volume":"29","author":"Stratigos","year":"2004","journal-title":"Clin Exp Dermatol"},{"key":"R82-7-20210226","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1046\/j.1365-2230.2003.01411.x","article-title":"Etanercept-induced systemic lupus erythematosus.","volume":"28","author":"Swale","year":"2003","journal-title":"Clin Exp Dermatol"},{"key":"R83-7-20210226","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s10067-006-0317-z","article-title":"Peripheral neuropathy in two patients with rheumatoid arthritis receiving infliximab treatment.","volume":"26","author":"Tektonidou","year":"2007","journal-title":"Clin Rheumatol"},{"key":"R84-7-20210226","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1093\/rheumatology\/kel227","article-title":"Onset of systemic lupus erythematosus after conversion of infliximab to adalimumab treatment in rheumatoid arthritis with a pre-existing anti-dsDNA antibody level.","volume":"45","author":"Van Rijthoven","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"R85-7-20210226","first-page":"1189","article-title":"Interstitial pneumonitis associated with infliximab therapy.","volume":"33","author":"Villeneuve","year":"2006","journal-title":"J Rheumatol"},{"key":"R86-7-20210226","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/01.MIB.0000219811.54115.aa","article-title":"Interstitial pneumonitis after infliximab therapy for Crohn's disease.","volume":"12","author":"Weatherhead","year":"2006","journal-title":"Inflamm Bowel Dis"},{"key":"R87-7-20210226","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jbspin.2005.04.004","article-title":"Cutaneous lymphocytic vasculitis during TNFalpha antagonist therapy for polyarthritis.","volume":"73","author":"Wendling","year":"2006","journal-title":"Joint Bone Spine"},{"key":"R88-7-20210226","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/art.20311","article-title":"Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients.","volume":"50","author":"Wolfe","year":"2004","journal-title":"Arthritis Rheum"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0b013e3181441a68","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:40:39Z","timestamp":1786034439000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00005792-200707000-00007"}},"subtitle":["Analysis of 233 Cases"],"short-title":[],"issued":{"date-parts":[[2007,7]]},"references-count":89,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0b013e3181441a68","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1089198.542397","asserted-by":"object"}]},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2007,7]]}}}